INT146342

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 6
Disease Relevance 3.34
Pain Relevance 3.40

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc6a3) plasma membrane (Slc6a3) transmembrane transport (Slc6a3)
Anatomy Link Frequency
substantia nigra 4
neuroblast 4
Slc6a3 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 108 100.00 Very High Very High Very High
fluoxetine 6 100.00 Very High Very High Very High
Desipramine 2 100.00 Very High Very High Very High
cocaine 222 99.98 Very High Very High Very High
Substantia nigra 6 99.78 Very High Very High Very High
monoamine 18 84.64 Quite High
Serotonin 4 80.04 Quite High
Eae 42 66.20 Quite High
Enkephalin 2 25.00 Low Low
Nucleus accumbens 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Parkinson's Disease 20 99.56 Very High Very High Very High
Apoptosis 14 96.52 Very High Very High Very High
Toxicity 6 89.04 High High
Drug Induced Neurotoxicity 4 75.68 Quite High
Targeted Disruption 10 5.00 Very Low Very Low Very Low
Sprains And Strains 8 5.00 Very Low Very Low Very Low
Attention Deficit Hyperactivity Disorder 8 5.00 Very Low Very Low Very Low
Aggression 2 5.00 Very Low Very Low Very Low
Drug Dependence 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Tamoxifen at 50 microg reduced the methamphetamine effect on striatal dopamine concentration, dopamine transporter specific binding and prevented the increase in preproenkephalin mRNA levels; in the substantia nigra tamoxifen prevented the decrease of dopamine transporter mRNA levels.
Negative_regulation (prevented) of Negative_regulation (decrease) of dopamine transporter in substantia nigra associated with dopamine and substantia nigra
1) Confidence 0.44 Published 2007 Journal Biochem. Pharmacol. Section Abstract Doc Link 17825264 Disease Relevance 0.24 Pain Relevance 0.58
Cocaine inhibition of SERT and/or NET in the absence of DAT inhibition in DAT-CI mice leads to locomotor suppression.
Negative_regulation (absence) of Negative_regulation (inhibition) of DAT associated with cocaine
2) Confidence 0.43 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1914080 Disease Relevance 0 Pain Relevance 0.66
Cocaine inhibition of SERT and/or NET in the absence of DAT inhibition in DAT-CI mice leads to locomotor suppression.
Negative_regulation (inhibition) of Negative_regulation (absence) of DAT-CI associated with cocaine
3) Confidence 0.37 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1914080 Disease Relevance 0 Pain Relevance 0.67
To examine whether these transporters are involved in MPTP-induced neuroblast apoptosis in the SVZ, terminal deoxynucleotidyl transferase-mediated dUTP endlabeling (TUNEL)-positive cells were semiquantitatively analyzed after the injection of GBR12909 (GBR), a DAT inhibitor; tetrabenazine (TBZ), a VMAT2 inhibitor; fluoxetine (FLU), a SERT inhibitor, or desipramine (DES), a NET inhibitor, prior to MPTP injection.
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of DAT in neuroblast associated with parkinson's disease, desipramine, apoptosis and fluoxetine
4) Confidence 0.36 Published 2009 Journal Neurotoxicology Section Abstract Doc Link 19616025 Disease Relevance 1.41 Pain Relevance 0.45
To examine whether these transporters are involved in MPTP-induced neuroblast apoptosis in the SVZ, terminal deoxynucleotidyl transferase-mediated dUTP endlabeling (TUNEL)-positive cells were semiquantitatively analyzed after the injection of GBR12909 (GBR), a DAT inhibitor; tetrabenazine (TBZ), a VMAT2 inhibitor; fluoxetine (FLU), a SERT inhibitor, or desipramine (DES), a NET inhibitor, prior to MPTP injection.
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of DAT in neuroblast associated with parkinson's disease, desipramine, apoptosis and fluoxetine
5) Confidence 0.36 Published 2009 Journal Neurotoxicology Section Abstract Doc Link 19616025 Disease Relevance 1.43 Pain Relevance 0.45
Tamoxifen at 50 microg reduced the methamphetamine effect on striatal dopamine concentration, dopamine transporter specific binding and prevented the increase in preproenkephalin mRNA levels; in the substantia nigra tamoxifen prevented the decrease of dopamine transporter mRNA levels.
Negative_regulation (decrease) of Negative_regulation (levels) of dopamine transporter in substantia nigra associated with dopamine and substantia nigra
6) Confidence 0.33 Published 2007 Journal Biochem. Pharmacol. Section Abstract Doc Link 17825264 Disease Relevance 0.24 Pain Relevance 0.58

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox